PRESS RELEASE: Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind October 31st 2023 Read More
Raising Funds in a Tight Market: Q&A With Sharon Cunningham, CEO of Shorla Oncology October 24th 2023 Read More
PRESS RELEASE: Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio October 4th 2023 Read More